Please enable Javascript
Hematology & Blood Cancer
Advertisement
APN Follow-Up May Improve Oral Chemotherapy Adherence and Safety in Multiple Myeloma
Cancer Nursing Today Editors
Multiple Myeloma
|
September 22, 2023
Although oral chemotherapy is convenient, adherence and safety must be monitored, especially in older patients.
Read More
3 Major Supportive Care Issues for Patients With Steroid-Refractory Chronic GVHD
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
GVHD
|
August 11, 2023
Infection, pain, and psychological distress can all adversely affect this patient population. What can be done?
Read More
3 Practice Implications From the Living With Chronic GVHD Patient Survey
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
GVHD
|
August 11, 2023
Disability leave, loss of income, and poor career opportunities were all challenges for patients with chronic GVHD.
Read More
Nutrition Status Predicts Likelihood of GVHD After AHSCT
Dustin Samples
GVHD
|
August 11, 2023
Enteral probiotics and prebiotics, along with vitamin D supplementation, may help prevent gut GVHD in AHSCT patients.
Read More
Porcine Anti-Thymocyte Globulin for Prevention of GVHD in HLA-Matched Sibling HSCT
Dustin Samples
GVHD
|
August 11, 2023
The treatment reduced the risk of aGVHD and cGVHD but did not improve non-relapse mortality or overall survival.
Read More
Lenalidomide, Dexamethasone, and Carfilzomib for Newly Diagnosed Multiple Myeloma
Dustin Samples
Multiple Myeloma
|
July 31, 2023
Using carfilzomib instead of bortezomib improved progression-free and overall survival and reduced toxicity.
Read More
Clonal Plasma Cells Are a Predictor for Worse OS After AHSCT in Multiple Myeloma
Dustin Samples
Multiple Myeloma
|
July 31, 2023
The difference was significant, with patients who received AHSCT with residual clonal plasma cells having much lower OS.
Read More
Attrition Rates in Multiple Myeloma Increase After Each Subsequent Line of Therapy
Dustin Samples
Multiple Myeloma
|
July 31, 2023
Though attrition rates increased, they were lower than previously reported.
Read More
Understanding the Psychosocial Impact of Advanced Multiple Myeloma
Olivia Thomas
Multiple Myeloma
|
July 26, 2023
Four themes were identified from patient telephone interview responses that summarized the experience of living with MM.
Read More
FDA Announces Changes to PI3Ki Accelerated Approval Process
Dustin Samples
Conferences
|
April 27, 2023
Accelerated approvals will no longer be granted based on overall response rates in single-arm trials.
Read More
Real-World Duration of Venetoclax Treatment Varied From Approved Dosing Schedule
Dustin Samples
Conferences
|
April 6, 2023
The approved dosing schedule for venetoclax is time-limited, but how many patients follow the schedule?
Read More
Origins and Underlying Mechanism of Sequential or Concurrent CLL/CML
Dustin Samples
Conferences
|
April 6, 2023
Though rare, CLL and CML sometimes occur sequentially or concurrently. But what is the mechanism behind the relationship?
Read More
Trial for Non-Melanoma Skin Cancer in Patients With CLL Now Enrolling
Dustin Samples
Conferences
|
April 6, 2023
In a currently enrolling trial, patients with CLL and NMSC will receive experimental treatment with nicotinamide.
Read More
Updated Treatment Guidelines for CLL/SLL
Dustin Samples
Conferences
|
April 6, 2023
Deborah Stephens, DO, presented the recommendations and algorithms for first-, second-, and third-line CLL/SLL therapy.
Read More
Recruitment Strategies for Nursing Students to Care for Patients With GVHD
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
GVHD
|
March 29, 2023
Graft-versus-host disease is the most life-threatening consequence of stem cell transplant, and nurses are urgently needed.
Read More
Mindfulness Meditation for People With GVHD and Their Caregivers
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
GVHD
|
March 29, 2023
The benefits of mindfulness meditation are numerous and far-reaching. But can they help HSCT recipients with GVHD?
Read More
Oral Dysbiosis Associated With Increased Risk of Posttransplant Disease, GVHD
Dustin Samples
GVHD
|
March 29, 2023
Certain species were predictive of not only the occurrence of GVHD, but also the severity.
Read More
Pruritus in Cutaneous GVHD Is Both Underreported and Understudied
Dustin Samples
GVHD
|
March 29, 2023
Pruritus is considered a mild adverse event, but does it negatively affect quality of life?
Read More
Novel Trio of Bortezomib, Dexamethasone, and Daratumumab in Pediatric Plasmacytic PTLD Treatment
Dustin Samples
Lymphoma
|
February 15, 2023
A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.
Read More
Technology-Based Psychosocial Intervention for Adolescent and Young Adult Survivors of ALL
Dustin Samples
Leukemia
|
January 17, 2023
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Read More
Load More
Advertisement
Advertisement
Advertisement